DiagnoCure joins the OTCQX Marketplace and S&P Corporation Records Listing

  DiagnoCure joins the OTCQX Marketplace and S&P Corporation Records Listing

PR Newswire

QUEBEC CITY, April 2, 2013

QUEBEC CITY, April 2, 2013 /PRNewswire/ - DiagnoCure, Inc. (TSX: CUR)  (OTCQX: 
DGCRF), today announced  that the Company's  stock is now  trading on OTCQX  ^ 
International  under  the  symbol  "DGCRF".   OTCQX  is  the  best  U.S.   OTC 
marketplace, providing  an opportunity  to significantly  broaden and  enhance 
DiagnoCure's access and exposure within the U.S. market. The OTCQX marketplace
has earned an exemplary reputation for providing U.S. investors with  improved 
liquidity, transparency, superior information,  and easy access through  their 
U.S. regulated broker dealers. It is  also recognized within the industry  for 
maintaining  rigid  quotation  standards  for  companies  that  trade   there. 
Investors can find current financial disclosures and Real-Time Level 2  quotes 
for DiagnoCure on www.otcmarkets.com.

In addition, DiagnoCure announced today thatits company information would  be 
made available viaStandard & Poor's  Corporation Records Listing Program.  As 
part of the program, a full description of DiagnoCure will be published in the
Daily News  Section of  Standard &  Poors' Corporation  Records, a  recognized 
securities manual for secondary trading in up to 38 states under the Blue  Sky 
Laws. Standard & Poor's Corporation Records is available in print, CD-ROM, and
via the  web  at  www.netadvantage.standardandpoors.com  as  well  as  through 
numerous electronic vendors.  The company information  about DiagnoCure to  be 
made available through this  program includes an  in-depth description of  the 
DiagnoCure's  business  operations,  share  price,  dividend  history,  shares 
outstanding, company financial position,  earnings, and full income  statement 
and balance sheet.

Canaccord Genuity will be  the market maker  of DiagnoCure's stock.  Canaccord 
Genuity is a global, full-service investment bank focused on growth  companies 
and is one of the largest market maker in the United States.

Dorsey & Whitney  LLP will  serve as DiagnoCure's  Principal American  Liaison 
("PAL") on OTCQX, responsible for providing guidance on OTCQX requirements and
U.S. securities laws.

"Trading on OTCQX International will provide enhanced access to U.S. investors
and the  ability  for DiagnoCure  to  diversify its  shareholder  base,"  said 
Chantal Miklosi,  Chief  Financial Officer  of  DiagnoCure. "We  believe  that 
trading on the OTCQX marketplace is  in the best interest of shareholders  and 
will enable the Company to enhance the market liquidity of DiagnoCure shares."

About DiagnoCure

DiagnoCure (TSX:  CUR;  OTCQX: DGCRF)  is  a life  sciences  corporation  that 
develops and commercializes high-value  cancer diagnostic tests that  increase 
clinician and patient  confidence in making  critical treatment decisions.  In 
2008, the Corporation launched  a colorectal cancer  staging test through  its 
U.S. CLIA laboratory. Previstage^TMGCC is currently available for  licensing. 
The Corporation has granted a worldwide exclusive license to Gen-Probe, now  a 
wholly-owned subsidiary of  Hologic Inc. (NASDAQ:  HOLX) operating as  Hologic 
Gen-Probe, for the development and commercialization of a prostate cancer test
using PCA3, DiagnoCure's proprietary molecular biomarker. Hologic  Gen-Probe's 
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is  approved 
for commercialization in Canada and  the United States. For more  information, 
visit www.diagnocure.com.

Forward‐looking statements

This release  contains "forward‐looking  statements,"  within the  meaning  of 
applicable United States and Canadian securities laws, that involve known  and 
unknown risks, uncertainties and assumptions that may cause actual results  to 
differ materially from those expected.  By their very nature,  forward‐looking 
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known  and  unknown,  many of  which  are  beyond  DiagnoCure's 
control. As a result, investors are  cautioned not to place undue reliance  on 
these forward‐looking statements. Such forward-looking statements include  the 
outcome  of  research  and  development  projects,  clinical  studies,  future 
revenues, the benefits of being quoted on the OTCQX and the improved liquidity
of the Company's shares when traded on  the OTCQX and are based on  management 
expectations. In addition, the  reader is referred  to the applicable  general 
risks  and  uncertainties  described   in  DiagnoCure's  most  recent   Annual 
Information Form under  the heading "Risk  Factors". DiagnoCure undertakes  no 
obligation  to  publicly  update  or  revise  any  forward‐looking  statements 
contained herein  unless  required  by  the  applicable  securities  laws  and 

SOURCE DiagnoCure inc.


DiagnoCure Inc.
Chantal Miklosi
Chief Financial Officer
(418) 527-6100

DiagnoCure Inc.
Geneviève Couture
Coordinator, Administration and Communications
(418) 527-6100
Press spacebar to pause and continue. Press esc to stop.